- Generic name
- Ibandronic Acid
- Strength
- 150 mg
- Dosage form
- Tablet
- Manufactured by
- Renata PLC.
Ivana F.C. Tablet
About Ivana F.C. 150 mg Tablet
Ivana F.C. 150 mg tablet is made by Renata PLC. and contains ibandronic acid, a bisphosphonate used in postmenopausal osteoporosis to help lower the risk of fractures.
There are 13 brands of Ibandronic Acid listed in Bangladesh. The lowest listed price is Bondrix 150 mg Tablet at ৳ 400.00 per unit.
What is Ivana F.C. 150 mg Tablet?
Ivana F.C. 150 mg tablet is a bisphosphonate preparation from Renata PLC. containing ibandronic acid. It is prescribed for postmenopausal osteoporosis, with the aim of reducing the risk of fractures. Osteoporosis may be confirmed by low bone mass and a history of osteoporotic fracture, or by low bone mass alone when no such fracture has been documented. Ibandronic acid works by slowing bone resorption. Because it is a prescription medicine, the doctor assesses each patient and decides whether it is suitable. The doctor also decides the dose and course, and how long treatment should continue.
Uses of Ivana F.C.
Ivana F.C. 150 mg tablet is used to treat osteoporosis in women after menopause, with the goal of reducing the risk of fractures. The doctor confirms osteoporosis using bone mass findings and the patient's fracture history, or bone mass findings alone in some cases. It belongs to the bisphosphonate group of medicines, which reduce bone breakdown. It is not a general tonic or a calcium supplement. Ask the doctor if you are unsure why it has been prescribed for you or what it is expected to do in your case.
How to use Ivana F.C.
The doctor decides the dose and course of Ivana F.C. 150 mg tablet. Swallow the tablet whole with a full glass of plain water while sitting or standing upright, and stay upright afterwards as your doctor or pharmacist advises. Plain water is the only drink to take with it. Other drinks, food, calcium and some other medicines can interfere with absorption, so the doctor or pharmacist will explain the timing. Do not lie down straight after taking it. Follow the instructions given to you exactly.
Side effects of Ivana F.C.
Side effects that may occur with ibandronic acid include indigestion, nausea, diarrhoea, abdominal pain, muscle aches, headache and dizziness. Tell your doctor promptly if you have trouble swallowing, pain on swallowing, heartburn, or stomach or chest pain, or if side effects are severe or do not settle. The doctor can advise whether you need to stop or change treatment. Do not start or stop the medicine on your own. Ask your pharmacist about anything you notice after taking it.
Safety and precautions
Ivana F.C. 150 mg tablet should not be used during pregnancy. Tell the doctor if you are pregnant, think you may be pregnant, or are breastfeeding, and ask about contraception advice. It is not for people with known hypersensitivity to ibandronic acid or the tablet's other ingredients, with uncorrected low calcium levels, or with certain oesophageal problems that delay emptying. It is also not for people who cannot sit or stand upright as instructed. The doctor should be told about active stomach or oesophageal problems, swallowing difficulty, or other medicines and supplements you take, and will decide whether it is suitable for you.
Frequently asked questions
What side effects should I watch for, and when should I call the doctor?
Watch for indigestion, nausea, diarrhoea, abdominal pain, muscle aches, headache and dizziness. Call your doctor promptly if you have difficulty or pain on swallowing, heartburn, or stomach or chest pain, or if side effects are severe or persistent. Ask your pharmacist if anything else worries you.
What is Ivana F.C. 150 mg tablet used for and what kind of medicine is it?
It is a bisphosphonate preparation containing ibandronic acid, made by Renata PLC. It is used to treat osteoporosis in women after menopause, aiming to reduce the risk of fractures. It works by slowing bone resorption. Your doctor will confirm whether it is appropriate for your condition.
How should I store Ivana F.C. 150 mg tablet?
Keep the tablets below 30°C, away from light and moisture, and out of the reach of children. Store them in the original packaging and do not use them after the expiry date. If you are unsure how to store them, ask your pharmacist for advice.
Can I take other medicines, supplements or food with it?
Calcium supplements, antacids and some medicines containing aluminium, magnesium or iron can interfere with absorption, so other oral medicines and supplements are usually taken after a waiting period. The doctor or pharmacist will explain the timing. Take the tablet with plain water only, and follow their instructions on food and other drinks.
Indications
Treatment of Osteoporosis: Osteoporosis may be confirmed by the finding of low bone mass (T-score <-2.0 SD) and the presence or history of osteoporotic fracture, or a low bone mass (T-score <-2.5 SD) in the absence of documented pre-existing osteoporotic fracture.
Pharmacology
Ibandronic acid is a highly potent bisphosphonate belonging to the nitrogen-containing group of bisphosphonates, which act on bone tissue and specifically inhibit osteoclast activity, It does not interfere with osteoclast recruitment. The selective action of ibandronic acid on bone tissue is based on the high affinity of this compound for hydroxyapatite, which represents the mineral matrix of the bone. Ibandronic acid reduces bone resorption, with no direct effect on bone formation. In postmenopausal women, it reduces the elevated rate of bone turnover towards premenopausal levels, leading to a progressive net gain in bone mass. Daily or intermittent administration of ibandronic acid results in reduced bone resorption as reflected in reduced levels of serum and urinary biochemical markers of bone turnover, increased BMD and a decreased incidence of fractures.
Dosage & Administration
- Tablets should be swallowed whole with a full glass of plain water (180 to 240 ml) while the patient is sitting or standing in an upright position. Patients should not lie down for 60 minutes after taking Ibandronic acid.
- Plain water is the only drink that should be taken with Ibandronic acid. Please note that some mineral waters may have a higher concentration of calcium and therefore should not be used.
- Patients should not chew or suck the tablet because of a potential for oropharyngeal ulceration. Patients should receive supplemental calcium or vitamin D if dietary intake is inadequate. In case a once-monthly dose is missed, patients should be instructed to take one Ibandronic Acid 150 mg tablet the morning after the tablet is remembered unless the time to the next scheduled dose is within 7 days. Patients should then return to taking their dose once a month on their originally scheduled date. If the next scheduled dose is within 7 days, patients should wait until their next dose and then continue taking one tablet once a month as originally scheduled. Patients should not take two 150 mg tablets within the same week.
Interaction
In relation to disposition, no drug interactions of clinical significance are considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats. Furthermore, plasma protein binding is low at therapeutic concentrations and ibandronic acid is therefore unlikely to displace other drugs. Ibandronic acid is eliminated by renal excretion only and does not undergo any biotransformation. The secretory pathway appears not to include known acidic or basic transport systems involved in the excretion of other drugs. In a one-year study in postmenopausal women with osteoporosis (BM16549). the incidence of upper gastrointestinal events in patients concomitantly taking aspirin or NSAIDs was similar in patients taking Ibandronic Acid 2.5 mg daily or 150mg once monthly. Of over 1500 patients enrolled in study BM 16549 comparing monthly with daily dosing regimens of ibandronic acid, 14% of patients used histamine (H2) blockers or proton pump inhibitors. Among these patients, the incidence of upper gastrointestinal events in the patients treated with Ibandronic Acid 150 mg once monthly was similar to that in patients treated with Ibandronic Acid 2.5 mg daily.
Contraindications
Side Effects
Pregnancy & Lactation
Nursing Mothers: Ibandronic Acid should not be used during lactation. In lactating rats treated with 0.08 mg/kg/day IV. ibandronic acid, the highest concentration of ibandronic acid in breast milk was 8.1 ng/ml and was seen in the first 2 hours after i.v. administration. After 24 hours, the concentration in milk and plasma was similar, and corresponded to about 5 % of the concentration measured after 2 hours.
Precautions & Warnings
Physicians should be alert to any signs or symptoms signaling a possible esophageal reaction and patients should be instructed to discontinue Ibandronic Acid and seek medical attention if they develop dysphagia, odynophagia, retrosternal pain or new or worsening heartburn. While no increased risk was observed in controlled clinical trials there have been post-marketing reports of gastric and duodenal ulcers with oral bisphosphonate use, some severe and with complications. Since NSAIDs and bisphosphonates are both associated with gastrointestinal irritation, caution should be taken during concomitant medication with Ibandronic Acid. Osteonecrosis of the jaw (ONJ) has been reported in patients treated with bisphosphonates. Most cases have been in cancer patients undergoing dental procedures, but some have occurred in patients with postmenopausal osteoporosis or other diagnoses. Known risk factors for osteonecrosis of the jaw include a diagnosis of cancer, concomitant therapies (e.g., chemotherapy, radiotherapy, corticosteroids), and co-morbid disorders (e.g., anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases have been in patients treated with bisphosphonates intravenously but some have been in patients treated orally. For patients who develop osteonecrosis of the jaw while on bisphosphonate therapy, dental surgery may exacerbate the condition. For patients requiring dental procedures, there are no data available to suggest whether discontinuation of bisphosphonate treatment reduces the risk of ONJ. Clinical judgment of the treating physician should guide the management plan of each patient based on individual benefit-risk assessment.
Overdose Effects
Storage Conditions
Alternative brands of Ibandronic Acid
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.